Cromolyn (Na)
Cromolyn (Na) Information

About Cromolyn (Na)

Cromolyn was synthesized in 1965, as part of an attempt to produce an improved bronchodilator copound. Although cromolyn does not have bronchodilator activity, it was found to inhibit antigen-induced bronchospasm. Currently, its major use is as a prophylactic agent in the treatment of mild to moderate asthma. Cromolyn (Na) is also used as a nasal inhaler to treat seasonal allergic rhinitis, as an ophthalmic solution to treat allergic or vernal conjunctivitis. Cromolyn sodium was approved by the FDA in 1973 and went off patent in May 1993.

Indications

Cromolyn (Na) is primarily indicated in conditions like Allergic conjunctivitis, Allergic rhinitis, Asthma, Food allergy, Perennial rhinitis, Seasonal rhinitis.

Contraindication

Cromolyn (Na) is contraindicated in conditions like Hypersensitivity.

Side Effects

The symptomatic adverse reactions produced by Cromolyn (Na) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Local irritation.

Warnings

Withdrawl may lead to recurrence of the symptoms of asthma. If withdrawl is necessary, it has been suggested that the dose should be reduce gradually over a period of one week.

High Risk Groups

Drug should not be given to Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.